<DOC>
	<DOCNO>NCT00289549</DOCNO>
	<brief_summary>Forodesine hydrochloride administer orally dose 200 mg daily 7 day week 4 week ( cycle number 1 ) . The drug administer daily one hour prior two hour meal . Patients evaluate 1 full cycle therapy ( 28 day ) .</brief_summary>
	<brief_title>Study Forodesine Hydrochloride Patients With Advanced , Fludarabine-refractory Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<criteria>Ages 18 year old Diagnosis CLL establish peripheral blood bone marrow examination use standard criterion Patients Rai stage III IV , early stage massive , symptomatic lymphadenopathy require therapy Primary resistance fludarabinebased therapy ( complete response [ CR ] partial response [ PR ] ) progressive disease within 6 month response prior fludarabine contain regimen . ECOG performance status 0 , 1 , 2 3 Willing take adequate contraception ( i.e . latex condom , cervical cap , diaphragm , abstinence , etc . ) entire duration study 3 month All investigational treatment discontinue least 1 week prior initiation study drug . Pregnant nursing Unable unwilling sign consent Severe , ongoing comorbid condition , would preclude safe delivery investigational therapy Active serious infection control antibiotic ECOG performance status 4 Inadequate renal function : creatinine 2.0 unless related disease Inadequate liver function : bilirubin 3.0 , transaminases 3 x upper limit normal unless related disease Known positive test HIV Patients know hepatitis B and/or hepatitis C active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>CLL</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>leukemia</keyword>
	<keyword>Advanced , fludarabine-refractory CLL</keyword>
</DOC>